Leerink Partnrs Issues Pessimistic Outlook for AGIO Earnings

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) – Analysts at Leerink Partnrs cut their Q2 2025 earnings per share (EPS) estimates for Agios Pharmaceuticals in a note issued to investors on Monday, April 28th. Leerink Partnrs analyst A. Berens now expects that the biopharmaceutical company will post earnings per share of ($1.81) for the quarter, down from their prior forecast of ($1.78). The consensus estimate for Agios Pharmaceuticals’ current full-year earnings is ($6.85) per share. Leerink Partnrs also issued estimates for Agios Pharmaceuticals’ Q3 2025 earnings at ($1.87) EPS, Q4 2025 earnings at ($2.22) EPS, FY2025 earnings at ($7.64) EPS, FY2026 earnings at ($7.31) EPS and FY2027 earnings at ($2.43) EPS.

A number of other equities analysts have also recently commented on the stock. StockNews.com raised shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday. HC Wainwright initiated coverage on Agios Pharmaceuticals in a research note on Monday, February 24th. They set a “buy” rating and a $58.00 price objective on the stock. Five investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $56.57.

Agios Pharmaceuticals Stock Performance

Shares of AGIO opened at $30.94 on Thursday. The stock has a market capitalization of $1.79 billion, a PE ratio of 2.73 and a beta of 0.83. The company’s fifty day moving average is $29.91 and its 200 day moving average is $37.92. Agios Pharmaceuticals has a fifty-two week low of $23.42 and a fifty-two week high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($1.55) earnings per share for the quarter, beating the consensus estimate of ($1.80) by $0.25. Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%.

Insider Activity

In related news, Director Jacqualyn A. Fouse sold 7,497 shares of the business’s stock in a transaction on Thursday, April 10th. The stock was sold at an average price of $25.90, for a total transaction of $194,172.30. Following the completion of the transaction, the director now owns 149,220 shares in the company, valued at $3,864,798. The trade was a 4.78 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 4.93% of the company’s stock.

Institutional Trading of Agios Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in AGIO. Venturi Wealth Management LLC purchased a new position in Agios Pharmaceuticals in the 4th quarter worth about $33,000. Franklin Resources Inc. bought a new stake in shares of Agios Pharmaceuticals during the third quarter valued at approximately $1,499,000. Vanguard Group Inc. boosted its holdings in shares of Agios Pharmaceuticals by 1.5% in the fourth quarter. Vanguard Group Inc. now owns 5,631,321 shares of the biopharmaceutical company’s stock valued at $185,045,000 after purchasing an additional 85,339 shares during the period. Bank of New York Mellon Corp grew its stake in Agios Pharmaceuticals by 48.8% in the fourth quarter. Bank of New York Mellon Corp now owns 265,514 shares of the biopharmaceutical company’s stock worth $8,725,000 after purchasing an additional 87,089 shares in the last quarter. Finally, Norges Bank purchased a new position in Agios Pharmaceuticals during the 4th quarter worth $4,768,000.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.